<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154874">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107391</url>
  </required_header>
  <id_info>
    <org_study_id>SP002</org_study_id>
    <secondary_id>2011-004986-34</secondary_id>
    <nct_id>NCT02107391</nct_id>
  </id_info>
  <brief_title>Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer</brief_title>
  <official_title>Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Combination With Hormone Therapy in Patients With Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/PCa  added onto hormone therapy can
      improve PSA progression times for patients with Metastatic Prostate Cancer (PCa).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of vaccine to improve Prostate Specific Antigen (PSA) levels.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients with PSA Progression</measure>
    <time_frame>104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Progression of Disease</measure>
    <time_frame>0, 6, 16, 28, 40, 52, 65, 78, 91, 104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>0, 2, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 52, 65, 78, 91, 104  weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Skeletal Related Events</measure>
    <time_frame>0, 2, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 52, 65, 78, 91, 104  weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life (QOL) assessed by EORTC QLQ-C30</measure>
    <time_frame>0, 16, 28, 40, 52, 52, 65, 78, 91, 104 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) form C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pain assessed by EORTC QLQ-C30</measure>
    <time_frame>0, 16, 28, 40, 52, 52, 65, 78, 91, 104 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain Scale from European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) form C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/PCA added Standard Hormone Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DCVAC/PCa added on to a Standard of Care Hormone Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Hormone Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/PCa</intervention_name>
    <description>Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy</description>
    <arm_group_label>DCVAC/PCA added Standard Hormone Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide acetate</intervention_name>
    <description>Standard of Care Hormone Therapy as an Active Comparator</description>
    <arm_group_label>Standard of Care Hormone Therapy</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Standard of Care Hormone Therapy as an Active Comparator</description>
    <arm_group_label>Standard of Care Hormone Therapy</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 18 years and older

          -  Histologically confirmed prostate adenocarcinoma

          -  Presence of bone or soft tissue metastasis (by CT or PET or MRI and/or scintigraphy)

          -  Androgen deprivation therapy using Luteinizing-hormone-releasing hormone ( LHRH)
             analogues commenced at least one month and at most three months prior randomization
             or orchiectomy performed at least one month and at most three months prior
             randomization

          -  Serum testosterone level at screening  (≤ 1.7 nmol/l, resp. ≤ 50 ng/dL)

          -  Eastern Cooperative Oncology Group (ECOG)  0-2

        Exclusion Criteria:

          -  Confirmed brain and/or leptomeningeal metastases

          -  Prior or ongoing chemotherapy for prostate cancer

          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater

          -  Other uncontrolled intercurrent illness

          -  Treatment with immunotherapy against PCa

          -  Clinically significant cardiovascular disease

          -  Active autoimmune disease requiring treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kromeriz</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mnisek pod Brdy</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pelhrimov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Biological</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Androgen Deprivation Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
